drugset / Trial / NCT04032626
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Phase 2
Completed
15 enrolled
St. Joseph's Hospital and Medical Center, Phoenix
National Institute on Aging (NIA) · collabThe Cleveland Clinic · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that modulating both systemic and CNS inflammation via the pleiotropic immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at a proper time window during the course of the disease.
Timeline
- Start
- 2020-07-22
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |